Abatacept
- Generic Name
- Abatacept
- Brand Names
- Orencia
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 332348-12-6
- Unique Ingredient Identifier
- 7D0YB67S97
- Background
Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of tw...
- Indication
Abatacept is indicated in adult patients for the treatment of moderately-to-severely active rheumatoid arthritis and for the treatment of active psoriatic arthritis. In patients two years of age and older, abatacept is also indicated for the treatment of moderately-to-severely active juvenile idiopathic arthritis.
...
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), Moderate to Severe Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Polyarticular juvenile rheumatoid arthritis, chronic or unspecified, Psoriatic Arthritis
- Associated Therapies
- -
A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2014-06-11
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Dinesh Khanna, MD, MS
- Target Recruit Count
- 88
- Registration Number
- NCT02161406
- Locations
- 🇺🇸
NorthWell Health, Great Neck, New York, United States
🇨🇦Mount Sinai Hospital, Toronto, Ontario, Canada
🇺🇸Arthritis Associates of Southern California, Los Angeles, California, United States
Long Term Experience With Abatacept in Routine Clinical Practice
- First Posted Date
- 2014-04-10
- Last Posted Date
- 2017-04-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 2364
- Registration Number
- NCT02109666
- Locations
- 🇨🇭
Local Institution, Basel, Switzerland
Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)
- Conditions
- Interventions
- First Posted Date
- 2014-04-09
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- University of South Florida
- Target Recruit Count
- 65
- Registration Number
- NCT02108860
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇨🇦University of Calgary, Calgary, Alberta, Canada
🇺🇸Vanderbilt University, Nashville, Tennessee, United States
Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background
- Conditions
- Interventions
- First Posted Date
- 2014-02-04
- Last Posted Date
- 2020-11-16
- Lead Sponsor
- University of California, Los Angeles
- Registration Number
- NCT02053727
- Locations
- 🇺🇸
Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, California, United States
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
- First Posted Date
- 2014-01-16
- Last Posted Date
- 2018-02-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 153
- Registration Number
- NCT02037737
Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study
- Conditions
- Interventions
- First Posted Date
- 2014-01-06
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- The Cleveland Clinic
- Registration Number
- NCT02027298
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata
- First Posted Date
- 2013-12-23
- Last Posted Date
- 2019-04-30
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 15
- Registration Number
- NCT02018042
- Locations
- 🇺🇸
Columbia University Medical Center - Department of Dermatology, New York, New York, United States
Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)
- First Posted Date
- 2013-10-07
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 56
- Registration Number
- NCT01954979
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Bone Marrow Transplant With Abatacept for Non-Malignant Diseases
- First Posted Date
- 2013-08-07
- Last Posted Date
- 2019-12-26
- Lead Sponsor
- Emory University
- Target Recruit Count
- 10
- Registration Number
- NCT01917708
- Locations
- 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
A Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata
- First Posted Date
- 2013-08-06
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Columbia University
- Registration Number
- NCT01917058
- Locations
- 🇺🇸
Columbia University Medical Center, Dept of Dermatology, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.